Efficacy of cyclin-dependent-kinase 9 inhibitors in a murine model of mixed-lineage leukemia

Leukemia

Volumn 28, Issue 7, 2014, Pages 1427-1435

  Garcia Cuellar, M P ^a   Fuller E ^a   Mathner E ^a   Breitinger, C ^a   Hetzner, K ^a   Zeitlmann, L ^b   Borkhardt, A ^c   Slany, R K ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b Ingenium Pharmaceuticals AG   (Germany)

^c Department of General Paediatrics   (Germany)

Author keywords

CDK9; inhibitor; mixed lineage leukemia; preclinical study

Indexed keywords

ALSTERPAULLONE; ANTILEUKEMIC AGENT; CYCLIN DEPENDENT KINASE 9; CYCLIN DEPENDENT KINASE 9 INHIBITOR; CYCLIN DEPENDENT KINASE INHIBITOR; FLAVOPIRIDOL; MYC PROTEIN; PC 142; PC 579; PC 585; RNA POLYMERASE II; TRANSCRIPTION FACTOR HOXA9; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CANCER SURVIVAL; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFICACY; GENE EXPRESSION; HUMAN; HUMAN CELL; LEUKEMIA; MIXED LINEAGE LEUKEMIA; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEPHOSPHORYLATION;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CYCLIN-DEPENDENT KINASE 9; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, LEUKEMIC; HUMANS; LEUKEMIA, BIPHENOTYPIC, ACUTE; MICE; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-MYC; RNA POLYMERASE II; TUMOR STEM CELL ASSAY; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84904044372     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2014.40     Document Type: Article

References (31)

1. Krauter J, Wagner K, Schafer I, Marschalek R, Meyer C, Heil G et al. Prognostic factors in adult patients up to 60 years old with acute myeloid leukemia and translocations of chromosome band 11q23 individual patient data-based metaanalysis of the German Acute Myeloid Leukemia Intergroup. J Clin Oncol 2009 27 3000-3006.
2. Pui CH, Carroll WL, Meshinchi S, Arceci RJ. Biology, risk stratification, and therapy of pediatric acute leukemias an update. J Clin Oncol 2011 29 551-565.
3. de Boer J, Walf-Vorderwulbecke V, Williams O. In focus MLL-rearranged leukemia. Leukemia 2013 27 1224-1228.
4. Slany RK. The molecular biology of mixed lineage leukemia. Haematologica 2009 94 984-993.
5. Lin C, Smith ER, Takahashi H, Lai KC, Martin-Brown S, Florens L et al. AFF4, a component of the ELL/P-TEFb elongation complex and a shared subunit of MLL chimeras, can link transcription elongation to leukemia. Mol Cell 2010 37 429-437.
6. Mueller D, Bach C, Zeisig D, Garcia-Cuellar MP, Monroe S, Sreekumar A et al. A role for the MLL fusion partner ENL in transcriptional elongation and chromatin modification. Blood 2007 110 4445-4454.
7. Mueller D, Garcia-Cuellar MP, Bach C, Buhl S, Maethner E, Slany RK. Misguided transcriptional elongation causes mixed lineage leukemia. PLoS Biol 2009 7 e1000249.
8. Yokoyama A, Lin M, Naresh A, Kitabayashi I, Cleary ML. A higher-order complex containing AF4 and ENL family proteins with P-TEFb facilitates oncogenic and physiologic MLL-dependent transcription. Cancer Cell 2010 17 198-212.
9. Zeisig BB, Milne T, Garcia-Cuellar MP, Schreiner S, Martin ME, Fuchs U et al. Hoxa9 and Meis1 are key targets for MLL-ENL-mediated cellular immortalization. Mol Cell Biol 2004 24 617-628.
10. Adelman K, Lis JT. Promoter-proximal pausing of RNA polymerase II emerging roles in metazoans. Nat Rev Genet 2012 13 720-731.
11. Peterlin BM, Price DH. Controlling the elongation phase of transcription with P-TEFb. Mol Cell 2006 23 297-305.
12. Mohan M, Herz HM, Takahashi YH, Lin C, Lai KC, Zhang Y et al. Linking H3K79 trimethylation to Wnt signaling through a novel Dot1-containing complex (DotCom). Genes Dev 2010 24 574-589.
13. Maethner E, Garcia-Cuellar MP, Breitinger C, Takacova S, Divoky V, Hess JL et al. MLL-ENL inhibits polycomb repressive complex 1 to achieve efficient transformation of hematopoietic cells. Cell Rep 2013 3 1553-1566.
14. Daigle SR, Olhava EJ, Therkelsen CA, Basavapathruni A, Jin L, Boriack-Sjodin PA et al. Potent inhibition of DOT1L as treatment of MLL-fusion leukemia. Blood 2013 122 1017-1025.
15. Daigle SR, Olhava EJ, Therkelsen CA, Majer CR, Sneeringer CJ, Song J et al. Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor. Cancer Cell 2011 20 53-65.
16. Dawson MA, Prinjha RK, Dittmann A, Giotopoulos G, Bantscheff M, Chan WI et al. Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia. Nature 2011 478 529-533.
17. Delmore JE, Issa GC, Lemieux ME, Rahl PB, Shi J, Jacobs HM et al. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell 2011 146 904-917.
18. Mertz JA, Conery AR, Bryant BM, Sandy P, Balasubramanian S, Mele DA et al. Targeting MYC dependence in cancer by inhibiting BET bromodomains. Proc Natl Acad Sci USA 2011 108 16669-16674.
19. Zuber J, Shi J, Wang E, Rappaport AR, Herrmann H, Sison EA et al. RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature 2011 478 524-528.
20. Lavau C, Szilvassy SJ, Slany R, Cleary ML. Immortalization and leukemic transformation of a myelomonocytic precursor by retrovirally transduced HRX-ENL. EMBO J 1997 16 4226-4237.
21. Takacova S, Slany R, Bartkova J, Stranecky V, Dolezel P, Luzna P et al. DNA damage response and inflammatory signaling limit the MLL-ENL-induced leukemogenesis in vivo. Cancer Cell 2012 21 517-531.
22. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA et al. Gene set enrichment analysis a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA 2005 102 15545-15550.
23. Bartholomeeusen K, Xiang Y, Fujinaga K, Peterlin BM. Bromodomain and extra-terminal (BET) bromodomain inhibition activate transcription via transient release of positive transcription elongation factor b (P-TEFb) from 7SK small nuclear ribonucleoprotein. J Biol Chem 2012 287 36609-36616.
24. Bernt KM, Zhu N, Sinha AU, Vempati S, Faber J, Krivtsov AV et al. MLL-rearranged leukemia is dependent on aberrant H3K79 methylation by DOT1L. Cancer Cell 2011 20 66-78.
25. Guenther MG, Lawton LN, Rozovskaia T, Frampton GM, Levine SS, Volkert TL et al. Aberrant chromatin at genes encoding stem cell regulators in human mixedlineage leukemia. Genes Dev 2008 22 3403-3408.
26. Wilkinson AC, Ballabio E, Geng H, North P, Tapia M, Kerry J et al. RUNX1 is a key target in t(411) leukemias that contributes to gene activation through an AF4-MLL complex interaction. Cell Rep 2013 3 116-127.
27. Loven J, Hoke HA, Lin CY, Lau A, Orlando DA, Vakoc CR et al. Selective inhibition of tumor oncogenes by disruption of super-enhancers. Cell 2013 153 320-334.
28. He N, Pezda AC, Zhou Q. Modulation of a P-TEFb functional equilibrium for the global control of cell growth and differentiation. Mol Cell Biol 2006 26 7068-7076.
29. Napolitano G, Amente S, Castiglia V, Gargano B, Ruda V, Darzacq X et al. Caffeine prevents transcription inhibition and P-TEFb/7SK dissociation following UV-induced DNA damage. PLoS One 2010 5 e11245.
30. Ramaswamy B, Phelps MA, Baiocchi R, Bekaii-Saab T, Ni W, Lai JP et al. A dose-finding, pharmacokinetic and pharmacodynamic study of a novel schedule of flavopiridol in patients with advanced solid tumors. Investig New Drugs 2012 30 629-638.
31. Barr PM. Flavopiridol Judged by the company one keeps. Leuk Res 2013 37 1187-1188.